ANTEROGEN CO., LTD. Logo

ANTEROGEN CO., LTD.

Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.

065660 | KO

Overview

Corporate Details

ISIN(s):
KR7065660003
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 130, 405호(가산동, 남성플라자), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Anterogen Co., Ltd. is a biotechnology company specializing in the research, development, and commercialization of cell therapy products and orphan drugs. The company's core technology leverages adult stem cells, particularly adipose-derived stem cells (ASCs), to create treatments for various medical conditions. Established with a research institute in 2000, Anterogen was a pioneer in the commercialization of ASC-based therapies in its domestic market. Its product pipeline is developed through clinical trials and focuses on leveraging the immune-modulating effects of its proprietary stem cell technology. The company manages the full lifecycle of its products, from research to manufacturing and distribution.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 813.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 798.1 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.9 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.0 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 17.8 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.0 MB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 132.6 KB
2025-02-20 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.3 KB
2025-02-20 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-02-10 00:00
Regulatory News Service
[기재정정]주요사항보고서(유상증자결정)
Korean 36.4 KB
2025-01-31 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.6 KB
2025-01-31 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (Wagner grade 1 당뇨병성 족부궤양 환자를 대상으로 한 ALLO-ASC…
Korean 11.4 KB
2025-01-23 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 25.9 KB
2024-12-09 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 762.7 KB

Automate Your Workflow. Get a real-time feed of all ANTEROGEN CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ANTEROGEN CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ANTEROGEN CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.